Drug Shortage Report for ADREVIEW
| Report ID | 124542 |
| Drug Identification Number | 02387034 |
| Brand name | ADREVIEW |
| Common or Proper name | Iobenguane (123I) Injection |
| Company Name | GE HEALTHCARE CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | IOBENGUANE 123 I |
| Strength(s) | 74MBq |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 5 mL |
| ATC code | V09IX |
| ATC description | |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2020-09-15 |
| Estimated end date | 2020-09-20 |
| Actual end date | 2020-09-20 |
| Shortage status | Resolved |
| Updated date | 2020-09-21 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 1919 MINNESOTA COURT MISSISSAUGA, ONTARIO CANADA L5N 0C9 |
| Company contact information | 800-387-7146 canadainfo@ge.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2020-09-18 | English | Compare |
| v2 | 2020-09-18 | French | Compare |
| v3 | 2020-09-21 | English | Compare |
| v4 | 2020-09-21 | French | Compare |
Showing 1 to 4 of 4